Oral psoriasis treatment SFA-002 improves disease severity within 6 weeks
Click Here to Manage Email Alerts
Key takeaways:
- 85% of patients achieved PASI 50, 71% achieved PASI 75 and two achieved PASI 100.
- No drug-related adverse events or toxicities were observed.
Based on results from a phase 1b trial, SFA-002 improved the signs and symptoms of chronic plaque psoriasis in patients within 6 weeks, SFA Therapeutics announced in a press release.
SFA-002 is an oral pill that down-regulates levels of pro-inflammatory cytokines involved in the pathogenesis of psoriasis including tumor necrosis factor-alpha, interferon‐gamma and multiple interleukin pathways.
The announced results are from the first cohort of the company’s phase 1b trial evaluating the effects of SFA-002 in patients with mild to moderate chronic plaque psoriasis.
The results are based on outcomes from 12 weeks of active therapy and a 1-month follow-up in 14 patients, as well as a 12-week extension period that included six of the patients.
Results showed that 85% of patients achieved PASI 50 or greater, 71% achieved PASI 75 or greater and two patients achieved PASI 100.
Improvement was observed within 6 weeks of treatment with no drug-related adverse events or toxicities emerging during active treatment or after the follow-up.
The phase 1b trial is ongoing with the second cohort currently being evaluated. Results from the second cohort are expected by the end of 2023.
Read more about
Click Here to Manage Email Alerts